Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways - Gilde Healthcare

Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways

20. Februar 2017

LONDON AND NEW YORK – Today at HIMSS, Lumeon, a leading digital health company, and Digital Noema Telehealth (DN Telehealth), a provider of telemedicine and remote patient monitoring, announce they are partnering to optimize care pathways for telemedicine reimbursements.

DN Telehealth maximizes collaboration compatibility for its clients and their patients, in real-time, extending consultations beyond a physical clinical setting to include fully secure, web browser-based conferencing sessions.  The solution allows clinicians, caregivers and patients to extend care coordination to go beyond traditional care models, to optimize care and promote patient engagement of any “at risk” patient population, in a fully HIPAA-compliant environment.

Lumeon’s Care Pathway Manager seamlessly integrates clinical and administrative systems, and gives providers the ability to design and automate their own pathway rules, so that each patient is automatically progressed through their personal care journey based on their individual data.

“We’ve been looking for a care pathway automation partner for quite some time,” said Roque Espinal-Valdez, founder, and CEO of DN Telehealth. “With Lumeon’s functionality to automate and orchestrate the care pathway, previously manual tasks are eliminated and we can ensure that reimbursable elements are consistently used to deliver predictable outcomes for our customers in the managed care market.”

“Working with DN Telehealth provides us with the opportunity to address one of the fastest growing sectors within healthcare,” said Robbie Hughes, Lumeon CEO. “At the same time, our platform will enable customers of DN Telehealth to automate and orchestrate their care pathways to maximize reimbursement and improve efficiency of care delivery.”

The solution is available in North American and European markets from March 2017.

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
16. Juli 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5. Juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21. Mai 2024